Relevant medical treatment following surgery and within the first 3 months among patients with significant pericardial effusions and without
| All | No significant pericardial effusion | With significant pericardial effusion | P value* | |
| N | 1460 | 1230 | 230 | |
| Anticoagulants | ||||
| Dalteparin | 623 (43) | 522 (42) | 65 (28) | ≤0.001 |
| Warfarin | 595 (41) | 457 (37) | 111 (48) | 0.002 |
| Phenprocoumon | 14 (1) | 13 (1) | <5 | 0.374 |
| Platelet aggregation inhibitors | ||||
| Acetylsalicyl acid | 1160 (79) | 1006 (82) | 134 (58) | ≤0.001 |
| Ticagrelor | 39 (3) | 35 (3) | <5 | 0.080 |
| Clopidogrel | 188 (13) | 152 (12) | 27 (12) | 0.793 |
| Dipyridamol | 34 (2) | 29 (2) | 5 (2) | 0.865 |
| Direct oral anticoagulants, DOAC | ||||
| Apixaban | 83 (6) | 73 (6) | 6 (3) | 0.041 |
| Dabigatranetexilat | 35 (2) | 29 (2) | 4 (2) | 0.562 |
| Rivaroxaban | 97 (7) | 87 (7) | 10 (4) | ≤0.001 |
| Combination of treatment | ||||
| Monotherapy, anticoagulants | 576 (39) | 472 (39) | 104 (45) | 0.051 |
| Dualtherapy, anticoagulants† | 794 (54) | 700 (57) | 94 (41) | ≤0.001 |
| Single antiplatelet therapy (SAPT) | 215 (15) | 175 (14) | 32 (14) | 0.619 |
| SAPT and anticoagulants | 1392 (95) | 1193 (97) | 199 (87) | ≤0.001 |
| Others | ||||
| Non-steroidal anti-inflammatory drug (NSAID), ibuprofen | 495 (34) | 388 (31) | 88 (38) | 0.046 |
*A p value <0.05 was considered statistically significant (shown in bold).
†Treatment with more than one type of anticoagulants.
DOAC, direct oral anticoagulants; NSAID, non-steriodal anti-inflammatory drug; SAPT, single antiplatelet therapy.